CAR-T Cell Research

We offer knockout cell lines for TCR, B2M, and CIITA, enabling the modeling of universal CAR-T cells. We also provide cell lines expressing common CAR targets like BCMA, CD19, CD20, and more, many of which include the luciferase reporter for simple monitoring. We also offer ready-to-use CAR-expressing cells for assay design/optimization and as positive controls in co-culture assays, as well as eGFP and Luciferase-expressing NK-92 cells for CAR-NK research.

Recombinant proteins can be used for a variety of purposes for CAR-T cell research. We provide biotin and PE-labeled versions of many of the target antigens for CARs, such as BCMA, CD19, CD22, CD38, CD123, and ROR1. These PE-labeled proteins can bind to CAR-T cells and be detected by flow cytometry, in order to verify CAR-T cell antigen recognition.

PBMCs (Peripheral Blood Mononuclear Cells) play a crucial role in CAR-T research. These cells, including T cells and other immune cells, are isolated from the patient's blood and can be engineered to express CAR receptors specific to cancer antigens. PBMCs serve as the starting material for CAR-T cell production, allowing researchers to study their efficacy, functionality, and potential for targeted cancer therapy.

Lentiviruses are well-suited for introducing CAR genes into primary cells, and our replication-incompetent lentiviruses are particularly advantageous due to their VSV-G pseudotyping. This enhances their safety, stability, and versatility across various cell types, especially T cells in culture. Our high-titer CAR lentivirus products allow for efficient transduction and sustained expression in both resting and actively dividing cells over extended periods of time.